Navigation Links
Intensive care quality of sleep improved by new drug, reports study

A new sedative drug has been shown to improve the sleep quality and comfort levels of intensive care patients, compared to the most commonly-used medication, according to research published today in the journal JAMA.

US and UK researchers compared the effects of the new drug dexmedetomidine with the commonly used sedative lorazepam, both of which reduce the pain and anxiety experienced by mechanically ventilated ICU patients and which help them to tolerate invasive procedures such as the insertion of catheters and feeding tubes.

While the routinely-administered lorazepam successfully lessens discomfort, it has also been associated with an increased risk of brain dysfunction, including coma and delirium, which prolong patients' time in hospital and raise the chance of death.

Now trials led by researchers at Vanderbilt University Schools of Medicine and Nursing in the US have shown that dexmedetomidine can provide better sedation and analgesia whilst at the same time reducing instances of coma and delirium.

The double-blind randomised controlled trials administered either dexmedetomidine or lorazepam for up to 120 hours to 106 volunteer adult mechanically ventilated ICU patients.

They found that around 30 per cent fewer patients in the dexmedetomidine group experienced coma, and that this group also experienced an average of four more coma-free and delirium-free days over study days one to 12 than those using lorazepam.

At the same time, dexmedetomidine proved to be a more effective sedative, with 80 per cent of the dexmedetomidine group sedated to the target level over the course of the trial, compared with 67% of the lorazepam group.

The study, carried out by researchers at Vanderbilt University, Tennessee, builds on the pioneering work of Professor Mervyn Maze of Imperial College London, who discovered and patented the sedative and hypnotic properties of dexmedetomidine in 1986, whilst he was at Stanford University.

This study is a very big step forward, said Professor Maze. Though it was not a large study in terms of number of patients, it conclusively shows that some sedative drugs have a more beneficial effect on sleep pathways than others."

Doctors estimate that an intensive care patient under sedation typically gets about two hours sleep out of every 24 hours. Professor Maze adds:

Good quality sleep, both coma-free and delirium-free, is critical for a patient in intensive care, as we know this can improve their chances of beating off further illness and infection, and ultimately their survival. The study shows that dexmedetomidine could be very good news for those very sick patients in ICU.

After 20 years of studying it, and understanding its mechanism of action and successfully predicting the application, its wonderful to have a demonstration of how the molecule actually improves the patients quality of life. Its a great example of how translational medical research brings benefit to patients.

After uncovering the molecular mechanism for its sedative effect in rodents, Professor Maze collaborated with Professor Nick Franks, also of Imperial College London, to understand how alpha-2 agonist drugs such as dexmedetomidine differ from benzodiazepine drugs such as lorazepam through studies of human volunteers.

The researchers hope that future studies measuring the quality of sleep experienced by ICU patients using different types of sedative will provide a greater understanding of the effects of the different drugs on brain dysfunction.


Contact: Laura Gallagher
Imperial College London

Related medicine news :

1. Large intensive care study reveals vital recommendations for treatment of brain injury patients
2. Browns Wives Host Special Day at MetroHealth Medical Center to Support the Neonatal Intensive Care Unit
3. Smoking Cessation Rates Double With Intensive Counseling and Free Nicotine Replacement Therapy, Studies of 20,000 Smokers Show
4. More proof needed of safety and quality of electronic personal health records
5. Pitt study finds inequality in tobacco advertising
6. Poor indoor air quality means poorer health for patients with COPD
7. Kingfisher Healthcare (KFH) Achieves World Class Quality Platform
8. Exempla Healthcare Contracts For Talismans Quality Donor System
9. Study finds primary care depression treatment often does not follow quality guidelines
10. Income inequality associated with overnourishment and undernourishment in India
11. Exercise and yoga improves quality of life in women with early-stage breast cancer
Post Your Comments:
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: